PHOENIX, May 13, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Avivagen Inc. (CHEXF), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. President, Chairman, and CEO, Kym Anthony, joined Stock Day host Everett Jolly.
Jolly began the interview by asking Mr. Anthony to give listeners an update on the Company’s current projects. Mr. Anthony explained that recently the Company has launched into the commercial space. With their new and existing customers, the Company has been able to more than double their volume. Another recent milestone is the beginning of the sales process in the United States. He further explained that the main product of the Company is a replacement for antibiotics in livestock feed, which has become incredibly popular overseas.
Mr. Anthony also explained that the Company recently formed a new partnership that will allow them to complete trials and begin selling their product in the United States, as well as expand their product into multiple applications.
Jolly then asked about the Company’s increasing revenues. “Those revenues come from two basic sources,” stated Mr. Anthony. He explained that currently the revenue is due to their sales for livestock additives, however another revenue source comes from their companion animal business which features an anti-inflammatory vitamin chew.
Jolly followed by asking about the Company’s future milestones. Mr. Anthony shared that United States trials and the transition of these trials into distribution represents their main goals. “The next 6-12 months, that will be the key thing to focus on,” stated Mr. Anthony. He also explained that the current product could also be applied as a supplement for humans to treat inflammation and other ailments in a healthy way.
Mr. Anthony shared that the Company’s livestock division is a major part of their revenues, however their future growth and revenues will be greatly enhanced by the addition of human applications for their products.
To close the interview, Mr. Anthony added that the Company plans to be moving their Vivamune Health Chews division to a joint venture with a major distribution platform which will further improve their revenues.
To hear Kym Anthony’s entire interview, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-kym-anthony-of-avivagen-inc-otcpink-chexf-4/
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the United States, Philippines, Taiwan, New Zealand and Thailand.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
About Vivamune™ Health Chews (Vivamune™)
Vivamune™ is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta™, Vivamune™ targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune™ is available for sale in the United States, Canada, Philippines and Taiwan. For more information, visit www.vivamunehealth.com. The contents of the website are expressly not incorporated by reference in this press release.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements about OxC-beta’s ability to replace antibiotics commonly added to livestock feeds or to fulfill the global mandate to remove in-feed antibiotics as growth promoters and the use of proceeds of the Offering set out in this news release are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approvals necessary to fulfill the global mandate to remove in-feed antibiotics as growth promoters and circumstances may require that Avivagen apply the net proceeds of the Offering differently than anticipated. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com
Kym Anthony
Interim Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Uptick Newswire
602-441-3474
https://upticknewswire.com/